Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

@inproceedings{Waddell2013EpirubicinOA,
  title={Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial},
  author={Tom S. Waddell and Ian Chau and David C. Cunningham and David Gonz{\'a}lez and Alicia Okines and Andrew Charles Wotherspoon and Claire Saffery and Gary William Middleton and Jonathan Charles Wadsley and David Ferry and Wasat Mansoor and Thomas David Lewis Crosby and Fareeda Y Coxon and David Smith and Justin S Waters and Timothy J Iveson and Stephen J. Falk and Sarah E Slater and Clare Peckitt and Yolanda Barbachano},
  booktitle={The Lancet. Oncology},
  year={2013}
}
BACKGROUND EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma. METHODS In this randomised, open-label phase 3 trial (REAL3), we enrolled patients with untreated, metastatic, or locally advanced oesophagogastric adenocarcinoma at 63 centres (tertiary referral… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
206 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 206 extracted citations

Similar Papers

Loading similar papers…